Abstract: The beneficial effects of fatty acids (FAs) on human health have attracted widespread interest. However, little is known about the impact of FAs on the handling of urate, the end-product of human purine metabolism, in the body. Increased serum urate levels occur in hyperuricemia, a disease that can lead to gout. In humans, urate filtered by the glomerulus of the kidney is majorly re-absorbed from primary urine into the blood via the urate transporter 1 (URAT1)-mediated pathway. URAT1 inhibition, thus, contributes to decreasing serum urate concentration by increasing net renal urate excretion. Here, we investigated the URAT1-inhibitory effects of 25 FAs that are commonly contained in foods or produced in the body. For this purpose, we conducted an in vitro transport assay using cells transiently expressing URAT1. Our results showed that unsaturated FAs, especially long-chain unsaturated FAs, inhibited URAT1 more strongly than saturated FAs. Among the tested unsaturated FAs, eicosapentaenoic acid, α-linolenic acid, and docosahexaenoic acid exhibited substantial URAT1-inhibitory activities, with half maximal inhibitory concentration values of 6.0, 14.2, and 15.2 µM, respectively. Although further studies are required to investigate whether the ω-3 polyunsaturated FAs can be employed as uricosuric agents, our findings further confirm FAs as nutritionally important substances influencing human health.

Keywords: Docosahexaenoic acid; eicosapentaenoic acid; functional food; gout; human health; hyperuricemia; PUFA; SLC22A12; transporter; uric acid; uricosuric activity
cancer [1]. However, little is known about the association between FAs and hyperuricemia, a common urate-related disease, especially regarding the effects of FAs on urate-handling machineries in the body.

Hyperuricemia, which is characterized by elevated serum uric acid (SUA) levels, is a lifestyle-related disease with high prevalence [6]. As hyperuricemia is a risk factor for gout, a very common form of inflammatory arthritis, SUA management at appropriate levels is becoming increasingly important in daily life [7,8]. Due to the lack of functional uricase (urate-degrading enzyme) in humans [9], uric acid is the end-product of human purine metabolism; urate excretion from the body is, therefore, necessary for the maintenance of uric acid homeostasis. The kidney is responsible for elimination of approximately two-thirds of urate [10]. However, only 3%–10% of the urate filtered by the glomerulus of the kidney is secreted to the urine [11] because most of it is re-absorbed from the primary urine into the blood in the proximal tubule by the urate transporter 1 (URAT1, also known as SLC22A12)-mediated pathway [12]. Thus, inhibition of this urate re-absorption pathway contributes to SUA lowering via the increase of net renal urate excretion.

URAT1 is a physiologically important renal urate re-absorber expressed on the brush border membrane of proximal tubular cells. Among the already identified urate re-absorbers expressed on the apical side of the renal cells, URAT1 is most strongly associated with SUA levels in humans [7], as supported by the fact that URAT1 is the causative gene for renal hypouricemia type 1 [12], an inherited disorder characterized by impaired urate re-absorption in the kidney that results in extremely low SUA levels (SUA \(\leq 2\) mg/dL; normal range: 3.0–7.0 mg/dL). With hyperuricemia patients, this transporter is also the pharmacological target of uricosuric agents, which promote the excretion of urate, such as benz bromarone [12], lesinurad [13], and dotinurad [14]. In this context, daily consumption of nutrients with URAT1-inhibitory activity may have a beneficial effect on SUA management in subjects with high SUA levels. Actually, food ingredients that inhibit URAT1 function have attracted great interest; we and other groups identified some such natural ingredients from fruit flavonoids [15], coumarins [16], and wood pigments [17]. Nevertheless, despite the nutritional significance of FAs, their effects on URAT1 activity remain to be elucidated.

In the present study, we examined the URAT1-inhibitory effects of 25 FAs using an in vitro transport assay with mammalian cells transiently expressing URAT1. The cell-based assay revealed that unsaturated FAs inhibited URAT1 more strongly than saturated FAs.

2. Materials and Methods

2.1. Materials

Critical materials and resources used in this study are summarized in Table 1. All other chemicals used were commercially available and of analytical grade. The FAs were re-dissolved with dimethyl sulfoxide (DMSO; Nacalai Tesque, Kyoto, Japan) after the solvents were gently evaporated with nitrogen gas on the heat block at 50 °C. All experiments were conducted with the same lot of each vector plasmid for URAT1 (URAT1 wild-type in pEGFP-C1) or mock (pEGFP-C1), which were derived from our previous study [15].

2.2. Cell Culture

Human embryonic kidney 293-derived 293A cells were maintained in Dulbecco’s modified Eagle’s medium (Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal bovine serum (Biowest, Nuaillé, France), 1% penicillin–streptomycin (Nacalai Tesque, Kyoto, Japan), 2 mM L-glutamine (Nacalai Tesque, Kyoto, Japan), and 1 × non-essential amino acid (Life Technologies, Carlsbad, CA, USA) at 37 °C in a humidified atmosphere of 5% (v/v) CO\(_2\) in air.

URAT1-expressing or mock plasmids were transfected into 293A cells using polyethyleneimine “MAX” (PEI-MAX) (Polysciences, Warrington, PA, USA) as described previously [18], with some modifications. In brief, before transfection, 293A cells were seeded onto 12-well cell culture plates at a concentration of 0.92 × 10^5 cells/cm\(^2\). Then, 24 h after seeding, each plasmid vector was transiently
transfected into the cells using PEI-MAX (1 µg of plasmid/5 µL of PEI-MAX/well). The medium was replaced with fresh medium 24 h after transfection.

Table 1. Key resources.

| Reagent or Resource | Source | Identifier |
|---------------------|--------|------------|
| Antibodies          |        |            |
| Rabbit polyclonal anti-EGFP | Life Technologies | Cat# A11122, RRID: AB_221569, 1:1,000 dilution ¹ |
| Rabbit polyclonal anti-α-tubulin | Abcam | Cat# ab15246, RRID: AB_301787, 1:1,000 dilution ¹ |
| Donkey anti-rabbit IgG-horseradish peroxidase (HRP)-conjugate | GE Healthcare | Cat# NA934V, RRID: AB_772206, 1:1,000 dilution ¹ |
| Chemicals          |        |            |
| [8-14C]-Uric acid (53 mCi/mmol) | American Radiolabeled Chemicals | Cat# ARC0513 |
| Arachidonic acid | Cayman Chemical | Cat# 20749, RRID: AB_221569, 1:1,000 dilution ¹ |
| Benz bromoromone | FUJIFILM Wako Pure Chemical | Cat# 028-1585, RRID: AB_301787, 1:1,000 dilution ¹ |
| Butyric acid | SIGMA-ALDRICH | Cat# B103500-5ML, RRID: AB_772206, 1:1,000 dilution ¹ |
| Deanoic acid | FUJIFILM Wako Pure Chemical | Cat# 033-01073, RRID: AB_221569, 1:1,000 dilution ¹ |
| Dimethyl sulfoxide | Nacalai Tesque | Cat# 13445-74, RRID: AB_221569, 1:1,000 dilution ¹ |
| Docosadienoic acid | Cayman Chemical | Cat# 20749, RRID: AB_221569, 1:1,000 dilution ¹ |
| Docosahexaenoic acid | Cayman Chemical | Cat# 90310, RRID: AB_221569, 1:1,000 dilution ¹ |
| Docosatetraenoic acid | Cayman Chemical | Cat# 90300, RRID: AB_221569, 1:1,000 dilution ¹ |
| Docosadienoic acid | SIGMA-ALDRICH | Cat# L556-25G, RRID: AB_221569, 1:1,000 dilution ¹ |
| Eicosadienoic acid | Cayman Chemical | Cat# 90110, RRID: AB_221569, 1:1,000 dilution ¹ |
| Eicosatrienoic acid | Cayman Chemical | Cat# 90179, RRID: AB_221569, 1:1,000 dilution ¹ |
| Eicosapentaenoic acid | Cayman Chemical | Cat# 90179, RRID: AB_221569, 1:1,000 dilution ¹ |
| Eicosatetraenoic acid | Cayman Chemical | Cat# 90192, RRID: AB_221569, 1:1,000 dilution ¹ |
| Henosapentaenoic acid | Cayman Chemical | Cat# 10670, RRID: AB_221569, 1:1,000 dilution ¹ |
| Hexanoic acid | FUJIFILM Wako Pure Chemical | Cat# 081-00292, RRID: AB_221569, 1:1,000 dilution ¹ |
| Linoleic acid | Cayman Chemical | Cat# 90150, RRID: AB_221569, 1:1,000 dilution ¹ |
| Oleic acid | Cayman Chemical | Cat# 90260, RRID: AB_221569, 1:1,000 dilution ¹ |
| Palmitic acid | Cayman Chemical | Cat# 10006627, RRID: AB_221569, 1:1,000 dilution ¹ |
| Palmitoleic acid | Cayman Chemical | Cat# 10009871, RRID: AB_221569, 1:1,000 dilution ¹ |
| Polyethyleneimine “MAX” | Polysciences | Cat# 24765, RRID: AB_221569, 1:1,000 dilution ¹ |
| Stearic acid | Cayman Chemical | Cat# 4751-1G, RRID: AB_221569, 1:1,000 dilution ¹ |
| α-Eleostearic acid | Cayman Chemical | Cat# 10008349, RRID: AB_221569, 1:1,000 dilution ¹ |
| α-Linolenic acid | Cayman Chemical | Cat# 90210, RRID: AB_221569, 1:1,000 dilution ¹ |
| γ-Linolenic acid | Cayman Chemical | Cat# 90220, RRID: AB_221569, 1:1,000 dilution ¹ |
| ω-3 Eicosapentaenoic acid | Cayman Chemical | Cat# 10-2024, RRID: AB_221569, 1:1,000 dilution ¹ |
| ω-3 Docosapentaenoic acid | Cayman Chemical | Cat# 90165, RRID: AB_221569, 1:1,000 dilution ¹ |
| Critical Commercial Assays |        |            |
| Pierce™ BCA Protein Assay Reagent A & B | Thermo Fisher Scientific | Cat# 23223, Cat# 23224 |
| PureLink™ HiPure Plasmid Filter Midiprep Kit | Thermo Fisher Scientific | Cat# 210015 |
| Recombinant DNA |        |            |
| The complete URAT1 cDNA | Miyata et al., 2016 [18] | NCBi Reference Sequence: NM_144585.3 |
| Experimental Models: Cell Lines |        |            |
| 293A | Invitrogen | R70507 |
| Software and Algorithms |        |            |
| Excel 2019 | Microsoft | https://products.office.com/ja-jp/business |
| Statec4 add-in software | OMS Publishing | http://www.oms-publ.co.jp/ |

¹ All antibodies were used at indicated dilutions in Tris-buffered saline containing 0.05% Tween 20 and 1% bovine serum albumin for 1 h at room temperature.

2.3. Preparation of Protein Lysates and Immunoblotting

Whole-cell lysates were prepared with cell lysis buffer A containing 50 mM Tris/HCl (pH 7.4), 1 mM dithiothreitol, 1% (w/v) Triton X-100, and protease inhibitor Complete, EDTA free (Roche, Basel, Switzerland), and were treated with peptide N-glycosidase F (PNGase F) (New England Biolabs, Ipswich, MA, USA) as described previously [19]. Protein concentration was determined using the
Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, Kanagawa, Japan) with BSA as a standard, according to the manufacturer’s protocol.

Whole-cell lysate samples were separated by SDS-PAGE and transferred to an Immobilon-P PVDF membrane (Millipore, Bedford, MA, USA) by electrophot blotting at 15 V for 60 min, as described previously [15]. Blots were probed with appropriate antibodies (Table 1), and the signals were visualized by chemiluminescence and detected using a multi-imaging Analyzer Fusion Solo 4™ system (Vilber Lourmat, Eberhardzell, Germany).

2.4. Confocal Microscopy

For confocal laser scanning microscopic observation, 48 h after the transfection, 293A cells were fixed with 4% paraformaldehyde for 15 min at room temperature, and further processed according to previous studies [15,20]. In brief, the cells were treated with a fluorescent wheat germ agglutinin conjugate (WGA, Alexa Fluor® 594 conjugate; Thermo Fisher Scientific) to visualize plasma membranes, followed by nuclear staining using TO-PRO-3 Iodide (Molecular Probes, Eugene, OR, USA). Then, the cells were mounted in VECTASHIELD Mounting Medium (Vector Laboratories, Burlingame, CA, USA). To analyze the localization of EGFP-fused URAT1 protein, fluorescence was observed using the FV10i Confocal Laser Scanning Microscope (Olympus, Tokyo, Japan).

2.5. Urate Uptake Assay Using URAT1-Expressing 293A Cells

The urate uptake assay using URAT1-expressing 293A cells was conducted according to our previous studies [15,18] with minor modifications. In brief, 48 h after plasmid transfection, cells were washed twice with Cl−-free transport buffer (Buffer T2: 125 mM Na-gluconate, 4.8 mM K-gluconate, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 1.3 mM Ca-gluconate, 25 mM HEPES, 5.6 mM D-glucose, and pH 7.4) and pre-incubated in Buffer T2 for 15 min at 37°C. The buffer was then exchanged with pre-warmed fresh Buffer T2 containing 5 µM [8-14C]-urate with or without test compound at the indicated concentrations (0, 0.1, 0.3, 1, 3, 10, 30, 100, or 300 µM), and the cells were further incubated for 20 sec; 1% DMSO was used as a vehicle control. The cells were subsequently washed five times with ice-cold Buffer T2 and then lysed with 500 µL of 0.2 M NaOH on ice with gentle shaking for 1 h. The lysates were neutralized with 100 µL of 1 M HCl. Then, the radioactivity in the lysate was measured using a liquid scintillator (Tri-Carb 3110TR; PerkinElmer, Waltham, MA, USA). The protein concentration was determined using the Pierce™ BCA Protein Assay Kit. The urate transport activity was calculated as the incorporated clearance (µL/mg protein/min): (incorporated level of urate [disintegrations per minute (DPM)/mg protein/min]/urate level in the incubation mixture [DPM/µL]). URAT1-dependent urate transport activity was calculated by subtracting the urate transport activity of mock cells from that of URAT1-expressing cells.

Urate uptake was measured in the presence of several concentrations of each test compound to address their half maximal inhibitory concentration (IC₅₀) values. URAT1-mediated transport activities were then expressed as a percentage of control (100%). Based on the calculated values, fitting curves were obtained according to the following formula using the least-squares method with Excel 2019 (Microsoft, Redmond, WA, USA):

\[
\text{Predicted value [%]} = 100 - \left( \frac{E_{\text{max}} \times C^n}{EC_{50}^n + C^n} \right)
\]

where \(E_{\text{max}}\) is the maximum effect, \(EC_{50}\) is the half maximal effective concentration, \(C\) is the concentration of the test compound, and \(n\) is the sigmoid-fit factor. Finally, based on the results, the IC₅₀ was calculated as described previously [15].

2.6. Quantification and Statistical Analysis

All statistical analyses were performed using Excel 2019 with Statcel4 add-in software (OMS publishing, Saitama, Japan). Different statistical tests were used for different experiments
as described in the figure legends, which include the number of biological replicates (n). Briefly, when analyzing multiple groups, the similarity of variance between groups was compared using Bartlett’s test. When passing the test for homogeneity of variance, a parametric Tukey–Kramer multiple-comparison test for all pairwise comparisons was used. To investigate the inhibitory effect of each FA on URAT1 function (vs. vehicle control indicated as 100%) in the screening stage, one-sample t-test (one-sided) was conducted. Statistical significance was defined as p < 0.05 or 0.01.

Each experiment was designed to use samples required to obtain informative results and sufficient material for subsequent studies. No specific statistical test was used to pre-determine the sample sizes empirically determined in the current study. All experiments were monitored in a non-blinded fashion.

3. Results

3.1. URAT1-Mediated Urate Uptake in 293A Cells

Prior to screening the inhibitory effects of 25 FAs on URAT1, we verified our cell-based assay system—an in vitro urate transport assay with mammalian cells transiently expressing URAT1 (Figure 1). Expression of EGFP-tagged URAT1 (EGFP-URAT1) as a matured N-linked glycoprotein (Figure 1a) and its plasma membrane localization (Figure 1b) in 293A cells were confirmed 48 h after plasmid transfection by immunoblotting and confocal microscopy, respectively. Next, we successfully detected URAT1-mediated urate uptake into URAT1-expressing cells, which showed a much stronger transport activity compared to mock cells, representing background urate uptake, indicating that the assay was suitable for the screening (Figure 1c). As expected, URAT1-mediated urate uptake was almost completely inhibited by benzbromarone (30 µM), a URAT1 inhibitor employed as a uricosuric drug. These results were consistent with our previous study [15]. A schematic illustration of this urate transport assay is shown in Figure 1d.

![Figure 1](image-url)
3.2. Unsaturated Fatty Acids Are Stronger Inhibitors of URAT1 Activity Than Saturated Fatty Acids

Next, we examined the inhibitory effects of 25 FAs—8 saturated (Figure A1) and 17 unsaturated (Figure A2) FAs—at a concentration of 100 µM on URAT1 function (Figure 2). Despite some exceptions, in this study, almost all of the unsaturated FAs showed a stronger inhibitory effect on URAT1 than saturated FAs. Among the eight saturated FAs, relatively short FAs with chain lengths ranging from C4 to C8 had little effect on URAT1-mediated urate transport; instead, the others (C10 to C18) mildly inhibited URAT1 at the screening concentration. This result suggested that the length of FA could have a substantial effect on the URAT1-inhibitory activity of FAs. Among the 17 unsaturated FAs, 9 inhibited URAT1 activity by over 50%. We therefore focused on these candidates.

![Figure 2.](image)

**Figure 2.** Inhibitory effects of each fatty acid on URAT1-mediated urate transport. The effects of each fatty acid (100 µM) on URAT1-mediated urate transport were investigated with the urate uptake assay. Control, vehicle (non-fatty acid treated) control. Data are expressed as the mean ± SD; n = 3–4. †, p < 0.05; ††, p < 0.01 vs. control (one-sample t-test). Red bars mean that the tested fatty acids inhibited URAT1-mediated urate transporter activity by over 50% compared to control.

3.3. ω-3 Fatty Acids Are the Most Effective URAT1 Inhibitors

Further investigation of the dose-dependent inhibitory effects of the nine unsaturated FAs on URAT1 determined the IC₅₀ values that are illustrated in Figure 3. Based on the IC₅₀ values, EPA was the strongest URAT1 inhibitor among the nine unsaturated FAs examined. Furthermore, EPA inhibited URAT1 activity more strongly than the other unsaturated FAs at low concentrations (≤1 µM) (Figure 3g). Second to EPA, its biosynthetic precursor α-linolenic acid (ALA) (Figure 3a) as well as its product DHA (Figure 3i) strongly inhibited URAT1, while ω-3 docosapentaenoic acid (DPA) showed an IC₅₀ of > 100 µM (Figures 2 and A3). Additionally, contrary to ALA, linoleic acid (LA) had a high IC₅₀ (133 µM); however, LA could inhibit URAT1 at low concentrations (≤1 µM) (Figure A3). Interestingly, considering the biosynthetic pathways of the above-described FAs distinguished by their structural feature (ω-3 or ω-6 family) (Figure A4), ω-3 FAs seem to inhibit URAT1 more effectively than ω-6 FAs. Given that elevated intake of ω-6 FAs may reportedly promote inflammation, while ω-3 FAs help reduce it [21], ω-3 FAs will be preferable to ω-6 FAs for the prevention of hyperuricemia/gout.
Figure 3. Concentration-dependent inhibition of URAT1-mediated urate transport by unsaturated fatty acids. The effects of each unsaturated fatty acid (0, 0.1, 0.3, 1, 3, 10, 30, 100, or 300 µM) on URAT1-mediated urate transport were investigated with the urate uptake assay. (a) α-Linolenic acid (ALA); (b) γ-linolenic acid; (c) eicosadienoic acid; (d) eicosatrienoic acid; (e) ω-3 eicosatetraenoic acid; (f) arachidonic acid (ω-6 eicosatetraenoic acid); (g) eicosapentaenoic acid (EPA); (h) henicosapentaenoic acid; (i) docosahexaenoic acid (DHA). Data are expressed as the mean ± SD; n = 4.

4. Discussion

In this study, to the best of our knowledge, we revealed for the first time the inhibitory effects of FAs on URAT1-dependent urate transport in vitro. While further studies are highly warranted to address the pathophysiological impact of our findings in terms of the possible effect on SUA and renal urate excretion in hyperuricemia model animals as well as in humans, the obtained results will open a new avenue for FAs as nutritionally important substances influencing human health.

Our findings may extend the potentially beneficial effects of PUFAs of the ω-3 family on reducing the risk of hyperuricemia/gout. In fact, recent studies have shown that a dietary intake of certain ω-3 PUFAs, such as EPA and DHA, can, at least partly, reduce a wide number of inflammation-related biological reactions [1,4,5,22]. With respect to gout, a small case–control study on patients with this inflammatory condition showed an association between high ω-3 FA levels in the blood and lower frequency of gout attacks [23]. Additionally, ω-3 PUFA-rich fish consumption was reportedly associated...
with lower risk of recurrent gout attacks in a case-crossover study [24]. Moreover, the anti-inflammatory effects of ω-3 PUFAs were supported by the results obtained in animal models of acute inflammation induced by monosodium urate crystals [25,26]. Thus, in addition to the anti-inflammatory effects previously observed, it should be confirmed in future studies whether ω-3 PUFAs can exhibit uricosuric effects in hyperuricemia models or not.

The potential effects of the daily consumption of ω-3 PUFA-enriched foods on SUA will also be of interest. While the available information is limited and currently inconclusive, a randomized controlled trial in young healthy subjects showed that daily intake of fish oil (2 g; majorly consisting of DHA and EPA) resulted in a significant decrease of SUA after 4 and 8 weeks of supplementation [27]. A similar significant decline in SUA was also observed in healthy elderly men consuming daily supplement pills characterized by ω-3 FAs such as DHA and EPA for three months, although the change was not extensive [28]. Based on these pieces of evidence, increasing the daily intake of ω-3 FAs via eating pattern changes, such as appropriate choice of aliments and cooking oils, might be beneficial to health in terms of SUA management. On the other hand, the behavior of ω-3 FAs in the body has been hardly investigated in those clinical investigations, which warrants further studies focusing on the beneficial effects of dietary and/or endogenously produced ω-3 FAs on the renal urate handling in the body. Additionally, in such cases, not only the URAT1-inhibitory activity but also the disposition of target FAs should be considered.

There were some limitations to our study. First, the present study could not reveal how the FAs inhibited URAT1 function. Addressing this issue in the future will provide a deeper insight into the latent mechanistic features of URAT1. As an antiporter, URAT1 mediates urate transport in exchange for monocarboxylates such as lactate [12], which suggests that URAT1 must have at least two substrate recognition sites in its protein structure. Considering that FAs are carboxylic acids with a long aliphatic chain, they might affect the recognition and/or subsequent membrane transport of the counterpart substrates by URAT1 rather than the recognition of urate. Second, we could not exclude the possibility that the FAs affected the plasma membrane properties, which might result in the indirect decrease of URAT1 function. Nonetheless, given that the interaction of free FAs with cellular membranes occurs within minutes [21] and usually requires biochemical conversion of FAs into phospholipids, the experimental period we used in this study, 20 s incubation for urate uptake, was so short that the tested FAs must have had a negligible effect on the plasma membranes during the assay. Finally, the effects of FAs on other physiologically important urate transporters—GLUT9/SLC2A9 [29,30], OAT10/SLC22A13 [31], and ABCG2/BCRP [32–34]—remain to be elucidated. Since such urate transporters, including URAT1, coordinately regulate the behavior of urate in the human body, comprehensive understanding of the latent interaction between FAs and these transporters should be addressed in the future. Among them, GLUT9 expressed on the basal membrane of proximal tubular cells is involved in the urate transport from the cells to the blood as a counterpart of URAT1 [7]; GLUT9 is the causative gene for renal hypouricemia type 2 [30]. Given these pieces of information, GLUT9 has the highest priority in the future investigation.

5. Conclusions

In conclusion, we herein found that FAs, especially ω-3 PUFAs such as EPA and DHA, could inhibit URAT1. To gain insight into the potential SUA-lowering effects of certain FAs, further investigations including human studies are required.

Author Contributions: Conceptualization, H.S. (Hiroki Saito), Y.T. (Yu Toyoda), and T.T.; methodology, H.S. (Hiroki Saito), Y.T. (Yu Toyoda) and H.H.; validation, H.S. (Hiroki Saito), Y.T. (Yu Toyoda) and T.T.; formal analysis, H.S. (Hiroki Saito) and Y.T. (Yu Toyoda); investigation, H.S. (Hiroki Saito), Y.T. (Yu Toyoda), H.H., A.O.-K. and H.M.; data curation, H.S. (Hiroki Saito), Y.T. (Yu Toyoda), and T.T.; writing—original draft preparation, H.S. (Hiroki Saito) and Y.T. (Yu Toyoda); writing—review and editing, Y.T. (Yu Toyoda) and T.T.; visualization, H.S. (Hiroki Saito) and Y.T. (Yu Toyoda); supervision, Y.T. (Youichi Tsuchiya) and H.S. (Hiroshi Suzuki); project administration, T.T. and N.K.; funding acquisition, T.T. All authors have read and agreed to the published version of the manuscript.
Funding: This study was supported by JSPS KAKENHI (grant numbers 16H01808 and 20H00568 to T.T.); T.T. has received research grants from Gout and uric acid foundation of Japan, MSD Life Science Foundation, Public Interest Incorporated Foundation, and Takeda Science Foundation. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgments: The authors thank Syuichi Segawa for his continuous encouragement and support for this study. Also, we would like to thank Editage (www.editage.jp) for English language editing.

Conflicts of Interest: H. Saito, H.H., A.O.-K., N.K., and Y.Tsuchiya were the employees of Sapporo Holdings Ltd. H.Saito, Y.Toyoda, T.T., H.H., A.O-K., and H. Suzuki have a patent pending related to the work reported in this article. The remaining authors declare no competing interests.

Appendix A

Figure A1. Chemical structures of saturated fatty acids tested in this study. (a) Butyric acid; (b) hexanoic acid; (c) octanoic acid; (d) decanoic acid; (e) dodecanoic acid; (f) myristic acid; (g) palmitic acid; (h) stearic acid.

Figure A2. Chemical structures of unsaturated fatty acids tested in this study. (a) Palmitoleic acid; (b) oleic acid; (c) linoleic acid; (d) α-linolenic acid (ALA); (e) γ-linolenic acid; (f) α-eleostearic acid; (g) eicosadienoic acid; (h) eicosatrienoic acid; (i) ω-3 eicosatetraenoic acid; (j) arachidonic acid (ω-6 eicosatetraenoic acid); (k) eicosapentaenoic acid (EPA); (l) henicosapentaenoic acid; (m) docosadienoic acid; (n) docosatetraenoic acid; (o) ω-3 docosapentaenoic acid; (p) ω-6 docosapentaenoic acid; (q) docosahexaenoic acid (DHA).
Figure A3. Concentration-dependent inhibition of URAT1-mediated urate transport by each fatty acid. Data are expressed as the mean ± SD; n = 4. (a) Linoleic acid; (b) ω-3 docosapentaenoic acid.

Figure A4. Biosynthetic route of fatty acids and half maximal inhibitory concentration (IC₅₀) values of each tested fatty acid against the urate transport mediated by URAT1. The IC₅₀ values are from Figures 2, 3 and A3. Three polyunsaturated fatty acids with substantial URAT1-inhibitory activities are indicated in red. N.D., not determined in this study; FAs, fatty acids; des, desaturase; elo, elongase. The metabolic pathway is adapted from a previous report [4], with some modifications.
References

1. Calder, P.C. Functional Roles of Fatty Acids and Their Effects on Human Health. *JPN J. Parenter. Enteral. Nutr.* 2015, 39, 185–32S. [CrossRef] [PubMed]

2. Nguyen, Q.V.; Malau-Aduli, B.S.; Cavaleri, J.; Malau-Aduli, A.E.O.; Nichols, P.D. Enhancing Omega-3 Long-Chain Polyunsaturated Fatty Acid Content of Dairy-Derived Foods for Human Consumption. *Nutrients* 2019, 11, 743. [CrossRef] [PubMed]

3. Shahidi, F.; Ambigaipalan, P. Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits. *Annu. Rev. Food Sci. Technol.* 2016, 9, 345–381. [PubMed]

4. Zarate, R.; El Jaber-Vazdeks, N.; Tejera, N.; Perez, J.A.; Rodriguez, C. Significance of long chain polyunsaturated fatty acids in human health. *Clin. Transl. Med.* 2017, 6, 25.

5. Bowen, K.J.; Harris, W.S.; Kris-Etherton, P.M. Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits? *Curr. Treat. Options Cardiovasc. Med.* 2016, 18, 69.

6. Dalbeth, N.; Merriman, T.R.; Stamp, L.K. Gout. *Lancet* 2005, 366, 199–201. [CrossRef]

7. Dalbeth, N.; Choi, H.K.; Joosten, L.A.B.; Khanna, P.P.; Matsuo, H.; Perez-Ruiz, F.; Stamp, L.K. Gout. *Nat. Rev. Dis. Primers.* 2018, 5, 69. [CrossRef]

8. Major, T.J.; Dalbeth, N.; Stahl, E.A.; Merriman, T.R. An update on the genetics of hyperuricaemia and gout. *Nat. Rev. Rheumatol.* 2018, 14, 341–353.

9. Wu, X.W.; Muzny, D.M.; Lee, C.C.; Caskey, C.T. Two independent mutational events in the loss of urate oxidase during hominoid evolution. *J. Mol. Evol.* 1992, 34, 78–84. [CrossRef]

10. Bobulescu, I.A.; Moe, O.W. Renal transport of uric acid: evolving concepts and uncertainties. *Adv. Chronic Kidney Dis.* 2012, 19, 358–371. [CrossRef]

11. Hyndman, D.; Liu, S.; Miner, J.N. Urate Handling in the Human Body. *Curr. Rheumatol. Rep.* 2016, 18, 34. [CrossRef] [PubMed]

12. Enomoto, A.; Kimura, H.; Chairoungdua, A.; Shigeta, Y.; Jutabha, P.; Cha, S.H.; Hosoyamada, M.; Takeda, M.; Saito, R.; Matsumoto, K.; Saito, H.; Sakai, M.; Chikamatsu, N.; Hagihara, C.; Hashiba, M.; Iwanaga, T. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor. *J. Pharmacol. Exp. Ther.* 2019, 371, 162–170. [CrossRef]

13. Toyoda, Y.; Takada, T.; Saito, H.; Hirata, H.; Ota-Kontani, A.; Kobayashi, N.; Tsuchiya, Y.; Suzuki, H. Inhibitory effect of Citrus flavonoids on the in vitro transport activity of human urate transporter 1 (URAT1/SLC22A12), a renal re-absorber of urate. *N.P.J. Sci. Food.* 2020, 4, 3. [CrossRef]

14. Tashiro, Y.; Sakai, R.; Hirose-Sugiura, T.; Kato, Y.; Matsuo, H.; Takada, T.; Suzuki, H.; Makino, T. Effects of Osthol Isolated from Cnidium monnieri Fruit on Urate Transporter 1. *Molecules* 2018, 23, 2837. [CrossRef]

15. Yu, Z.; Fong, W.P.; Cheng, C.H. Morin (3,5,7,2’,4’-pentahydroxyflavone) exhibits potent inhibitory actions on urate transporter 1 expressed in human embryonic kidney cells. *Drug. Metab. Dispos.* 2007, 35, 981–986. [CrossRef]

16. Miyata, H.; Takada, T.; Toyoda, Y.; Matsuo, H.; Ichida, K.; Suzuki, H. Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations. *Front. Pharmacol.* 2016, 7, 518. [CrossRef]

17. Toyoda, Y.; Sakurai, A.; Mitani, Y.; Nakashima, M.; Yoshiura, K-I.; Nakagawa, H.; Sakai, Y.; Ota, I.; Lezhava, A.; Hayashizaki, Y.; et al. Earwax, osmidrosis, and breast cancer: why does one SNP (538G>A) in the human ABC transporter ABCG11 gene determine earwax type? *FASEB J.* 2009, 23, 2001–2013. [CrossRef]

18. Toyoda, Y.; Manicova, A.; Krylov, V.; Morimoto, K.; Pavelcová, K.; Bohatá, J.; Pavelka, K.; Suzuki, H.; Matsuo, H.; Takada, T.; et al. Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort. *Cells* 2019, 8, 363. [CrossRef]

19. Ibarguren, M.; Lopez, D.J.; Escriba, P.V. The effect of natural and synthetic fatty acids on membrane structure, microdomain organization, cellular functions and human health. *Biochim. Biophys. Acta.* 2014, 1838, 1518–1528. [CrossRef]
22. Calder, P.C. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? *Br. J. Clin. Pharmacol.* 2013, 75, 645–662. [CrossRef] [PubMed]
23. Abhishek, A.; Valdes, A.M.; Doherty, M. Low omega-3 fatty acid levels associate with frequent gout attacks: a case control study. *Ann. Rheum. Dis.* 2016, 75, 784–785. [CrossRef] [PubMed]
24. Zhang, M.; Zhang, Y.; Terkeltaub, R.; Chen, C.; Neogi, T. Effect of Dietary and Supplemental Omega-3 Polyunsaturated Fatty Acids on Risk of Recurrent Gout Flares. *Arthritis Rheumatol.* 2019, 71, 1580–1586. [CrossRef] [PubMed]
25. Iverson, C.; Bacong, A.; Liu, S.; Baumgartner, S.; Lundstrom, T.; Oscarsson, J.; Miner, J.N. Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation. *Sci. Rep.* 2018, 8, 1217. [CrossRef] [PubMed]
26. Tate, G.A.; Mandell, B.F.; Karmali, R.A.; Laposata, M.; Baker, D.G.; Schumacher, H.R., Jr; Zurier, R.B. Suppression of monosodium urate crystal-induced acute inflammation by diets enriched with gamma-linolenic acid and eicosapentaenoic acid. *Arthritis Rheum.* 1988, 31, 1543–1551. [CrossRef] [PubMed]
27. Huang, T.; Li, K.; Asimi, S.; Chen, Q.; Li, D. Effect of vitamin B-12 and n-3 polyunsaturated fatty acids on plasma homocysteine, ferritin, C-reaction protein, and other cardiovascular risk factors: a randomized controlled trial. *Asia. Pac. J. Clin. Nutr.* 2015, 24, 403–411.
28. Stea, T.H.; Stolevik, S.B.; Berntsen, S.; Ezzathkah Bastani, N.; Paulsen, G.; Lohne Seiler, H.; Hetlelid, K.J.; Blomhoff, R.; Mansoor, M.A. Effect of Omega-3 and Vitamins E + C Supplements on the Concentration of Serum B-Vitamins and Plasma Redox Aminothiol Antioxidant Status in Elderly Men after Strength Training for Three Months. *Ann. Nutr. Metab.* 2016, 68, 145–155. [CrossRef]
29. Vitart, V.; Rudan, I.; Hayward, C.; Gray, N.K.; Floyd, J.; Knott, S.A.; Kolcic, I.; Polasek, O.; Graessler, J.; Wilson, J.F.; et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. *Nat. Genet.* 2008, 40, 437–442. [CrossRef]
30. Matsuo, H.; Chiba, T.; Nagamori, S.; Nakayama, A.; Domoto, H.; Phetdee, K.; Wiriyasermkul, P.; Kikuchi, Y.; Oda, T.; Nishiyama, J.; et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. *Am. J. Hum. Genet.* 2008, 83, 744–751. [CrossRef]
31. Higashino, T.; Morimoto, K.; Nakaoka, H.; Toyoda, Y.; Kawamura, Y.; Shimizu, S.; Nakamura, T.; Hosomichi, K.; Nakayama, A.; Ooyama, K.; et al. Dysfunctional missense variant of OAT10/SLC22A13 decreases gout risk and serum uric acid levels. *Ann Rheum Dis* 2020, 79, 164–166. [CrossRef] [PubMed]
32. Ichida, K.; Matsuo, H.; Takada, T.; Nakayama, A.; Murakami, K.; Shimizu, T.; Yamanashi, Y.; Kasuga, H.; Nakashima, H.; Nakamura, T.; et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. *Nat. Commun.* 2012, 3, 764. [PubMed]
33. Matsuo, H.; Takada, T.; Ichida, K.; Nakamura, T.; Nakayama, A.; Ikebuchi, Y.; Ito, K.; Kusanagi, Y.; Chiba, T.; Tadokoro, S.; et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: A function-based genetic analysis in a Japanese population. *Sci. Transl. Med.* 2009, 1, 5ra11. [CrossRef] [PubMed]
34. Woodward, O.M.; Kottgen, A.; Coresh, J.; Boerwinkle, E.; Guggino, W.B.; Kottgen, M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. *Proc. Natl. Acad. Sci. USA* 2009, 106, 10338–10342. [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).